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Abstract
Genetic variants resulting in non-expression of complement C4A and C4B genes are common in healthy European
populations and have shown association with a number of diseases, most notably the autoimmune disease, systemic lupus
erythematosus. The most frequent cause of a C4 ‘‘null’’ allele, following that of C4 gene copy number variation (CNV), is a
non-sense mutation arising from a 2 bp CT insertion into codon 1232 of exon 29. Previous attempts to accurately genotype
this polymorphism have not been amenable to high-throughput typing, and have been confounded by failure to account
for CNV at this locus, as well as by inability to distinguish between paralogs. We have developed a novel, high-throughput,
paralog-specific assay to detect the presence and copy number of this polymorphism. We have genotyped healthy cohorts
from the United Kingdom (UK) and Spain. Overall, 30/719 (4.17%) individuals from the UK cohort and 8/449 (1.78%)
individuals from the Spanish cohort harboured the CT insertion in a C4A gene. A single Spanish individual possessed a C4B
CT insertion. There is weak correlation between the C4 CT insertion and flanking MHC polymorphism. Therefore it is
important to note that, as with C4 gene CNV, disease-association due to this variant will be missed by current SNP-based
genome-wide association strategies.
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Introduction
The human complement C4 locus, located in the class III region
of the major histocompatibility complex (MHC) on the short arm
of chromosome 6, is highly polymorphic and exhibits genetic
complexity. Complement C4 genes show segmental duplication as
part of mono-, bi-, tri-, or quadri-modular RCCX cassettes.
RCCX modules comprise the following four genes encoded in
tandem - RP1 ( now known as STK19), cytochrome P450 steroid-
21 hydroxylase (CYP21A2), complement C4, and tenascin B
(TNXB). Two to eight copies of C4 genes may be present in a
diploid human genome; with each chromosome 6 comprising 1 to
4 copies of a C4 gene. The C4 gene exists as either of two paralogs:
C4A (acidic) (MIM: 120810) or C4B (basic) (MIM: 120820), each of
which is polymorphic in itself. At the nucleotide level, C4A and
C4B share 99% sequence homology over 41 exons. Each paralog is
defined by five nucleotide changes in exon 26, which contribute to
four isotype-specific amino acid residues from positions 1120 to
1125: PCPVLD for C4A and LSPVIH for C4B [1,2]. In addition,
C4 genes may vary in size depending on the presence (21 kb) or
absence (14.6 kb) of an intron 9 HERV-K(C4) insertion resulting
in long and short forms, respectively.
Genetic variants resulting in non-expression of C4A and C4B
genes (so-called ‘‘null’’ alleles, C4A*Q0 and C4B*Q0) are common
in healthy European populations and have shown association with
a number of diseases, most notably the autoimmune disease,
systemic lupus erythematosus (SLE/lupus; MIM: 152700)
[3,4,5,6]. The majority of C4A or C4B ‘‘null’’ alleles arise as a
consequence of copy number variation (CNV) at the C4 locus
where either paralog is absent from a particular haplotype. For
example, some MHC haplotypes harbour mono-modular RCCX
cassettes which comprise either C4A or C4B. Hence, the alternate
C4 paralog will be physically absent and not expressed at transcript
or protein level. Other C4 null alleles result from non-sense
mutations in C4A and C4B genes leading to the absence of the
respective protein. The most frequent cause of a C4 null allele,
following that of CNV, is a non-sense mutation arising from a 2 bp
CT insertion into codon 1232 of exon 29 in C4. This causes a
frameshift change in the C4 gene which alters the subsequent
amino acid sequence and results in a termination codon in exon 30
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[7]. Additional non-sense mutations that have been described in
the literature tend to show restriction to rare families demonstrat-
ing complete homozygous C4 deficiency: these include a G to A
substitution at the donor site of the intron 28 splice junction, a
1 bp deletion in exon 20, a 2 bp deletion in exon 13, a 1 bp
deletion in exon 13, a C to T transition in exon 13, and a 4 bp
insertion in exon 36, on a variety of haplotypic backgrounds
[7,8,9].
In the past, the presence of C4 null alleles was inferred from the
absence or reduced level of C4A or C4B proteins from serum or
plasma. Partial deficiency of C4A or C4B described the
phenomenon by which one isotype was expressed at about half
the level of the other. The absence or unequal serum/plasma
protein levels of C4A and C4B can be caused by the physical
absence or non-sense mutations of the corresponding gene, the
unequal number of C4A and C4B genes in a diploid genome, and
Figure 1. Schematic representation of paralog-specific complement C4 exon 29 CT insertion assay design. The top panel illustrates
exons 26 through to 29 of the complement C4 gene. The paralog-specific nucleotide changes in exon 26 are shown in the blue box. The CT insertion
in exon 29 is represented by the red box. The second panel depicts the FAM-labelled 864 bp amplicon obtained post-PCR. The third and fourth
panels show the C4A and C4B paralog-specific digestion products respectively.
doi:10.1371/journal.pone.0022128.g001
Figure 2. Cloned complement C4 exon 29 sequence. Electropherogram demonstrating (1) normal complement C4 exon 29 sequence and (2)
complement C4 exon 29 CT insertion (arrowed).
doi:10.1371/journal.pone.0022128.g002
C4 CNV in Healthy UK and Spanish Populations
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differential protein expression levels governed by the presence of
long or short C4 genes. Therefore, such ‘‘immunophenotyping’’
methods are not accurate measures of genetic variation at the C4
locus.
As previously mentioned the non-sense mutation resulting from
a CT insertion into exon 29 of the C4 gene is a frequent cause of
C4 deficiency. Previous attempts to accurately genotype this
polymorphism have not been amenable to high-throughput
typing, have been confounded by failure to account for CNV at
this locus, as well as inability to distinguish between C4A and C4B
[7,10,11,12,13,14,15]. We have developed a novel, high-through-
put, paralog-specific assay to determine the presence and copy
number of the exon 29 CT insertion within the C4 gene using
nanogram quantities of DNA. For the first time, we have
examined the frequency, SNP-CNV correlation and HLA
association of this polymorphism in healthy cohorts from the
United Kingdom and Spain. We have integrated these data with
that of total complement C4 gene copy number (GCN), C4A GCN
and C4B GCN using our previously published paralog ratio test
(PRT) [16].
Methods
Study Cohorts
1958 British Birth Cohort. 719 unrelated subjects from the
1958 British Birth Cohort that had been previously genotyped to
high-density at the MHC using a custom Illumina panel were
typed for the complement C4 exon 29 CT insertion using our novel
assay [17]. Two-digit HLA-DRB1 genotypes were available for
661/719 (92%) of the subjects. The SNP and HLA-DRB1 genotype
data were used for SNP-CT insertion CNV correlation analyses.
UK Family Cohort. The inheritance of the complement C4
exon 29 CT insertion was traced in 15 UK families, comprising 15
UK SLE probands who carried the insertion and 46 of their first
Figure 3. Complement C4 gene copy number distributions in healthy United Kingdom and Spanish populations. From left to right, the
histograms demonstrate total complement C4 gene copy number (GCN), C4A GCN and C4B GCN distributions in healthy United Kingdom (blue bars)
and Spanish (red bars) populations.
doi:10.1371/journal.pone.0022128.g003
C4 CNV in Healthy UK and Spanish Populations
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degree relatives. All probands fulfilled the American College of
Rheumatology criteria for SLE [18].
Spanish Control Cohort. The Spanish cohort comprised
460 healthy, unrelated individuals, including 253 subjects from
Granada and 207 subjects from Barcelona. 2553 ancestry
informative markers (AIMs) and 4179 SNP genotypes across the
MHC region were available for all subjects. The samples from
Granada were typed using a custom Illumina panel as part of the
IMAGEN consortium study (manuscript in submission). The
samples from Barcelona were typed using the Illumina 1 million
OMNI-Quad chip. Four-digit HLA-DRB1 data was available for
232/460 (50%) of the subjects. These data were used for SNP-CT
insertion CNV analyses.
Informed written consent was obtained from all study participants.
This study was approved by the London Research Ethics
Committee (Ref: 06/MRE02/9), United Kingdom, the Comite´ de
E´tica del CSIC, Granada, Spain and the Clinical Research Ethics
Committee of Vall d’Hebron University Hospital, Barcelona,
Spain.
Assessment of population substructure and relatedness
in Spanish cohort
All quality control analyses were performed separately for each
cohort using PLINK except principal components analysis which
was performed using EIGENSTRAT [19,20]. Samples and SNPs
were put forward for analysis if they met the following quality
control filters: SNPs greater than 95% genotyping efficiency, MAF
greater than 1%, samples greater than 95% genotyping efficiency
and PI-Hat scores less than 0.2 on identity-by-state analysis using
2553 ancestry informative markers (AIMs) in order to exclude
cryptic relatedness and duplicate samples. SNPs were excluded for
deviation from Hardy-Weinberg equilibrium on the basis of a false
discovery rate (FDR) of 0.05. In order to correct for population
stratification, samples were excluded if they were outliers on
principal components analysis using post-QC AIMs (performed
using EIGENSTRAT and defined as greater than 6 standard
deviations from the mean).
Complement C4 paralog ratio test
All study individuals were typed for total complement C4 gene
copy number (GCN), C4A GCN and C4B GCN using our
previously described paralog ratio test [16].
Complement C4 exon 29 CT insertion Assay Design
We based our assay on the principles of a restriction enzyme
digest variant ratio analysis (REDVR). A PCR was designed to
amplify a fragment spanning exon 26 of the C4 gene, where the
conserved, isotype-specific sequence differences are located, to
exon 29, where the CT insertion is located (Figure 1). Following
PCR amplification, the fragments were digested with PshAI, a
restriction enzyme recognising a site present within the paralog-
specific sequence of C4A but not C4B. Digestion products were
then separated using capillary electrophoresis, resulting in size-
specific peaks for C4A (794 bp) and C4B (864 bp). The presence of
the CT insertion in either of the two paralogs resulted in a peak
shifted by two base pairs compared to the wild-type. For
individuals heterozygous for the CT insertion in either C4A or
C4B, a specific pattern of clearly separated double peaks was
observed: the first peak corresponding to the normal copy(ies) and
the second peak corresponding to the copy(ies) of the gene
possessing the CT insertion (Figure S1). For individuals that were
homozygous or hemizygous for the CT insertion, i.e. all copies of
the C4 gene harboured the CT insertion or all copies of a
particular isotype, either C4A or C4B, harboured the CT insertion,
a single peak shifted by two base pairs from the expected normal
peak was seen. DNA from samples suggestive of homozygous or
hemizygous states was mixed with DNA from the PGF cell line
post PCR amplification. PGF is a MHC homozygous cell line with
two normal copies each of C4A and C4B; therefore if the test
sample was homozygous for the CT insertion in either/both C4A
or C4B, the double peak pattern would be observed following
capillary electrophoresis. The ratio of the area under the peak for
insertion-positive and insertion-negative amplicons was used in
combination with total C4 gene copy number data to determine
the number of C4 copies carrying the insertion in an individual.
Specifically, for the initial PCR, the 864 bp fragment (spanning
exon 26 to exon 29) was amplified using 25 ng (2.5 ml at 10 ng/ml)
of genomic DNA and 2.5 mM forward primer, REDVRA_F
(CTGAGAAACTGCAGGAGACATC) and 2.5 mM of 6-FAM
labelled reverse primer, CTinsR ([6FAM]GACACGGCATT-
GCTCTGA). The reaction volume was 25 ml, comprising 2.5 ml
of 106 PCR Buffer (QIAGEN), 0.5 mM of each dATP, dCTP
,dGTP and dTTP (Promega, Cat. No. U1240), 0.625 units of Taq
DNA polymerase (Qiagen, Cat.No. 201205) and 14.375 ml of
sterile water. PCR reaction conditions were: initial denaturation
step at 94uC for 3 min, followed by 25 cycles at 94uC for 30 sec,
58uC for 30 sec and 72uC for 1 min, followed by a chase phase of
56uC for 1 min and 70uC for 20 min to ensure complete addition
of the terminal adenine residue.
Following amplification, 10 ml PCR product was digested using
5 U of PshAI restriction enzyme (NEB, Cat. No. R0593L) in 20 ml
digestion reaction, comprising 2 ml 106NEB Buffer 4, 0.2 ml 1006
BSA and 7.3 ml of sterile water. The digestion reaction was
incubated at 37uC for 1 hour. 3 ml of digested product mixed with
9.5 ml HiDi Formamide was denatured at 96uC for 3 minutes,
placed on ice, and then analysed on a capillary sequencer (ABI
3730xl DNA analyzer, Applied Biosystems, using a 50 cm array)
with 0.5 ml per sample of the marker LIZ1200 (Applied Biosystems
Cat. No. 4379950). Following capillary electrophoresis, specific
Figure 4. Frequency of the complement C4 exon 29 CT
insertion in healthy United Kingdom and Spanish populations.
The histograms show the frequency of the complement C4 exon 29 CT
insertion in C4A and C4B in United Kingdom (blue bar) and Spanish (red
bars) populations.
doi:10.1371/journal.pone.0022128.g004
C4 CNV in Healthy UK and Spanish Populations
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C4A and C4B peaks could be seen at 794 bp and 864 bp
respectively (Figure S1).
All reactions were performed in 96-well plates. Each plate
included six controls: four DNA samples from cell lines of known
C4 genotype (COX: total C4 GCN = 2, C4A GCN = 0, C4B
GCN = 0; QBL: total C4 GCN = 2, C4A GCN = 2, C4B GCN = 0;
PGF: total C4 GCN = 4, C4A GCN = 2, C4B GCN = 2 and DBB:
total C4 GCN = 4, C4A GCN = 2, C4B GCN = 2), and two CEU
samples from the same family: 1416-12 (NA 12249) and 1416-1
(NA 10835) which have been previously shown to harbour the CT
insertion in a C4A gene [21] (ML Lokki, personal communication).
Cloning
For validation, we cloned two samples harbouring CT insertions
in C4A and C4B respectively, determined by our novel assay, using
the TOPO TA CloningH kit (Invitrogen, K4560-01). One sample
had a homozygous CT insertion in C4A and the other possessed a
heterozygous C4B CT insertion. For each sample, 4 ml of
undigested PCR product was added to 1 ml of sterile water and
1 ml of TOPOH vector. The mix was incubated for 5 minutes at
room temperature. 2 ml of the mix was added to a vial of
electrocompetent One Shot TOP10 cells followed by electropo-
ration (capacitance 25 mF, resistance 200 ohms, voltage 2.5 KV).
250 ml of SOC medium was added to the cells post-electroporation
followed by an hour’s incubation at 37uC and 200 rpm. The
electroporated cells were spread on S-Gal LB agar plates
containing 100 mg/ml ampicillin and incubated at 37uC over-
night. Clear colonies were chosen and cultured overnight in 5 ml
of LB Broth containing 50 mg/ml ampicillin. Plasmid DNA was
extracted from the cells using the High Pure Plasmid Isolation Kit
(Roche, Cat. No. 11 754 785 001). The cloned DNA was
sequenced to confirm the presence of the CT insertion in the C4
isotype of interest (Figure 2).
SNP-C4 CT insertion CNV correlation
In order to determine the relationship between the complement
C4 exon 29 CT insertion and surrounding MHC polymorphism
we calculated the correlation coefficient, r2, between SNP and
HLA-DRB1 genotypes and integer copy number estimates for the
CT insertion in C4A using standard linear regression as described
previously [16]. We used 2-digit HLA-DRB1 data for 1958 British
Birth Cohort subjects and 4-digit HLA-DRB1 data for the Spanish
control cohort. We used MHC region SNP data as previously
described: 1230 SNPs for the UK cohort and 4179 for the Spanish
dataset. We plotted the correlation coefficient, r2, against the
chromosomal position of each SNP for C4A CT insertion copy
number estimates. The size of the square representing each SNP is
inversely proportional to the p-value. C4B CT insertion analyses
were not performed as only a single Spanish individual possessed
the polymorphism.
Results
We have developed a novel, paralog-specific assay to detect the
presence of a common complement C4 null allele: a 2 bp CT
insertion in exon 29 of the complement C4 gene. We have
genotyped 719 United Kingdom (UK) individuals from the 1958
British Birth Cohort and 460 healthy Spanish individuals for the
polymorphism using this assay. In addition, we determined total
complement C4 GCN, C4A GCN and C4B GCN in both cohorts
using our previously described paralog ratio test [16].
Healthy Spanish individuals display higher complement
C4 gene copy numbers compared with healthy subjects
from the United Kingdom
In the UK cohort, total C4 GCN ranged from 2 to 6, with copy
numbers from 0 to 4 observed for both C4A and C4B (Figure 3).
Mean total C4 GCN was 3.89 (60.76), mean C4A GCN was 2.08
(60.83) and mean C4B GCN was 1.81 (60.72). The frequency of
C4A null homozygotes was 1.25% while that of C4B null
homozygotes was greater at 3.60%.
In the Spanish cohort, 11/460 individuals (2.39%) (9/207
individuals from Barcelona and 2/253 individuals from Granada)
were removed due to relatedness or population outliers, resulting
in a post-QC cohort size of 449 individuals. We observed a
broader range of C4 GCN estimates in this cohort compared with
the UK cohort: total C4 GCN varied from 2 to 8; C4A GCN from
0 to 6 and C4B GCN from 0 to 5 (Figure 3). Higher mean C4
GCNs were observed in the Spanish dataset in comparison to the
UK cohort: mean total C4 GCN was 4.13 (SD61.02) (p,0.0001),
mean C4A GCN was 2.20 (SD60.78) (p = 0.46) and mean C4B
GCN was 1.94 (SD60.86) (p = 0.11). The frequency of homozy-
gous C4A null alleles (1.10%) was similar to that observed in the
UK cohort (1.25%). However, homozygous C4B null alleles were
observed less frequently in the Spanish (2.60%) compared with the
UK cohort (3.60%).
The complement C4 exon 29 CT insertion occurs more
frequently in United Kingdom populations compared
with Spanish populations
Overall, 30/719 individuals (4.17%) from the UK cohort
harboured the CT insertion in C4A (Figure 4). 26 of 719
individuals (3.61%) harboured the CT insertion in a single C4A
gene and at least one additional normal copy of the gene; 2/719
individuals (0.28%) possessed the CT insertion in two copies of
C4A and one additional normal copy; a single individual (0.14%)
had the insertion in three copies of C4A and a fourth, normal
copy; a single individual (0.14%) had the insertion in the only
copy of the gene, resulting in complete C4A deficiency. The
frequency of chromosomes carrying a C4A CT insertion was
2.08%. CT insertions in C4B were not observed in the UK
cohort.
Eight of the 449 individuals in the Spanish cohort (1.78%)
possessed the CT insertion in a C4A gene, a much lower
frequency than that observed in individuals from the UK
(p = 0.02) (Figure 4). Six (1.34%) individuals had the insertion in
one copy of C4A plus one normal copy of C4A. One (0.22%)
individual had the insertion in one copy of C4A plus two normal
copies of the gene, and one individual had the insertion in one
copy of C4A plus three normal copies of C4A. We did not observe
any individuals with complete C4A deficiency solely due to the
presence of the exon 29 CT insertion. We did not detect any
individuals with more than one copy of the CT insertion in C4A
in the Spanish dataset, whereas in the UK cohort three
individuals harboured more than one copy of the polymorphism,
Figure 5. Mendelian inheritance pattern of the complement C4 exon 29 CT insertion. The genetic pedigrees illustrate 15 SLE families
where the SLE proband harbours a CT insertion together with a single CEU trio where mother and son are known to harbour the CT insertion in C4A.
Open squares identify healthy males, open circles identify healthy females, red squares indicate SLE affected males and red circles indicate SLE
affected females. Open bars indicate C4A genes and blue bars indicate C4B genes. Black triangles identify the presence of the C4 exon 29 CT insertion.
doi:10.1371/journal.pone.0022128.g005
C4 CNV in Healthy UK and Spanish Populations
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none of which occurred in conjunction with HLA-DRB1*13. It is
unclear whether this observation is genuine or is consequent
upon the larger size of the UK cohort. The frequency of
chromosomes harbouring the C4A CT insertion was less than
half that observed in the UK cohort at 0.89%. A single
individual possessed a C4B CT insertion, in addition to a
functional C4B copy, resulting in a frequency of chromosomes
bearing C4B CT insertions of 0.11%.
The complement C4 exon 29 CT insertion demonstrates
Mendelian inheritance
In order to determine the inheritance pattern of the comple-
ment C4 exon 29 CT insertion, we examined DNA from first
degree relatives (parents and siblings) of 15 UK SLE probands
known to harbour the C4 CT insertion in either C4A or C4B
(Figure 5). We did not find evidence of non-Mendelian
inheritance in any of the families, further validating our method.
Figure 6. Correlation between C4 exon 29 CT insertion and flanking MHC SNPs and HLA-DRB1 alleles. The correlation coefficient, r2,
between the C4 exon 29 CT insertion and flanking MHC SNPs and HLA-DRB1 alleles is shown. Data for the United Kingdom cohort is illustrated in the
top panel while that for the Spanish cohort is shown in the bottom panel. The sizes of the diamonds are inversely proportional to the p values for
each SNP or HLA-DRB1 allele. Purple diamonds indicate r2.0.4, red diamonds indicate r2.0.2 but ,0.4, blue diamonds indicate r2,0.2.
doi:10.1371/journal.pone.0022128.g006
C4 CNV in Healthy UK and Spanish Populations
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The C4 exon 29 CT insertion shows strong linkage
disequilibrium with HLA-DRB1*13
HLA-DRB1 genotypes were available for 33 of the 39 samples
carrying the CT insertion (84%): 28 of 30 UK samples (93%) and
5 out of 9 Spanish samples (55%). Overall, 78% of C4 CT
insertions were observed in individuals carrying at least one HLA-
DRB1*13 allele. In the UK cohort, 82% (23/28) of individuals
carried the CT insertion together with at least one DRB1*13 allele,
while in the Spanish cohort 60% (3/5) of individuals carried the
CT insertion in concert with at least one DRB1*13 allele,
representing the greater haplotypic diversity of southern European
populations or the smaller sample size of the Spanish cohort. No
other HLA-DRB1 alleles were over-represented among individuals
carrying the polymorphism (Table S1).
C4A CT insertion CNV-SNP correlation
We used linear regression to assess correlation between the C4A
CT insertion and surrounding SNPs and HLA-DRB1 alleles in the
UK and Spanish cohorts (Figure 6 and Table S2). We did not
find evidence of strong SNP-C4A CT insertion correlation.
In the UK dataset, the SNPs most highly correlated with the
C4A CT insertion were located in the class III region of the MHC,
telomeric to the RCCX module: rs2734331 – a synonymous SNP
in exon 11 of SKIV2L (r2 = 0.43), rs453098 - a synonymous SNP in
exon 2 of C6orf25 (r2 = 0.20), rs707915 in intron 5 of MSH5
(r2 = 0.20) and rs400547 in intron 5 of CLIC1 (r2 = 0.20). The HLA-
DRB1*13 allele has an r2 of 0.12 with the C4A CT insertion,
demonstrating that while most C4A CT insertions appear on a
HLA-DRB1*13 background, the majority of HLA-DRB1*13
haplotypes do not harbour the C4A CT polymorphism.
SNP-C4A CT insertion correlation values were lower in the
Spanish compared with the UK cohort, reflecting the greater
diversity of MHC haplotypes present in the Spanish population.
The SNPs showing the greatest correlation were again seen in the
class III region, telomeric and centromeric to the RCCX module:
rs2228088 - a synonymous SNP in exon 1 of TNF (r2 = 0.25) and
rs11964779 in intron 5 of MSH5 (r2 = 0.12), rs6927077 (r2 = 0.25),
rs6457580 (r2 = 0.25) and rs6940690 (r2 = 0.25), all near BTNL2, as
well as in the class II region of the MHC: rs6902390 (r2 = 0.12)
near HLA-DPA1 and rs10947368 - a synonymous SNP in exon 2 of
HLA-DOA (r2 = 0.12).
The degree of correlation is such that neither SNPs nor HLA-
DRB1 alleles can be used as surrogate markers for the C4A exon 29
CT insertion.
Discussion
We have developed a high-throughput, paralog-specific assay to
detect the presence and copy number of an exon 29 complement
C4 CT insertion which results in non-expression of C4 at the
protein level. This is important because C4 null alleles, inferred
from immunophenotyping studies, have shown association with
many disease states including the autoimmune disease, SLE. It is
clear that complete homozygous deficiency of complement C4 is a
strong genetic risk factor for SLE. However, due to the extended
linkage disequilibrium shown by disease-associated haplotypes
containing mono-modular RCCX cassettes in European popula-
tions, it remains to be determined whether partial C4 deficiency
due to low functional C4 gene copy number rather than complete
deficiency of the protein is also an independent risk factor for SLE.
If partial C4 deficiency is indeed important in disease susceptibil-
ity, then any genetic variant resulting in non-expression of C4
should also show association with disease. As the C4 CT insertion
occurs on haplotypic backgrounds that are different to those
harbouring mono-modular RCCX cassettes, it should be possible
to detect disease-association if the population frequency of the CT
insertion is reasonable given an appropriately powered study.
Our UK frequency data for total C4 GCN, C4A GCN and C4B
GCN are consistent with previous European-American reports
[22]. The Spanish data are novel and show higher total C4 GCN
compared to the UK cohort. As total complement C4 GCN, C4A
GCN and C4B GCN are greater in the Spanish cohort, the
number of functional complement C4 copies are also likely to be
higher than northern European UK individuals.
The C4 exon 29 CT insertion generally occurs on a HLA-
DRB1*13 haplotypic background. The frequency of all HLA-
DRB1*13 alleles is higher in the Spanish cohort (12.25%)
compared to the UK dataset (10.44%). Interestingly, the frequency
of the C4 exon 29 CT insertion is lower in the Spanish cohort
compared with the UK. This may be due to the greater variety of
HLA-DRB1*13 haplotypes in the Spanish population.
We confirm that the C4 CT insertion occurs almost exclusively
in association with C4A on a HLA-A*02-HLA-C*03:04-HLA-
B*40:01-HLA-DRB1*13(:02)-HLA-DQB1*06:04 haplotypic back-
ground, which was previously serologically defined as HLA-B60-
HLA-DR6 (Table S1) [7]. Following investigation of both cohorts,
we found only a single Spanish individual with a CT insertion in
C4B. These data are consistent with the CT insertion/mutation
initially occurring on an ancestral HLA-B60-C4A-HLA-DR6
haplotype. Subsequent recombination events have resulted in the
presence of the polymorphism on diverse haplotypes. The rare
occurrence of the mutation in C4B has been demonstrated in
previous studies and most likely represents a gene conversion event
[11,12].
There is weak correlation between the C4 CT insertion and
flanking MHC polymorphism. Therefore it is important to note
that, as with C4 CNV, disease-association due to this variant will
be missed by current SNP-based genome-wide association studies.
We plan to use this assay in conjunction with our PRT method
to estimate functional complement C4 gene copy number in SLE
cohorts of differing ancestry in order to elucidate the association
and independence of C4 CNV in this genetically complex
autoimmune disease.
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